论文部分内容阅读
目的 探讨ras和p5 3基因过度表达在甲状腺癌发生中的相互作用 ,以及甲状腺癌的临床病理标准与ras和 p5 3基因过度表达的关系。 方法 采用LSAB免疫组化法检测了ras和 p5 3在 80例甲状腺病变中的表达 ,其中 5 4例为甲状腺癌 ,2 6例为良性甲状腺结节性病变。结果 ras和 p5 3在甲状腺癌和良性甲状腺结节性病变中的表达阳性率分别为 90 .7%及 2 3 .0 %和 5 5 .5 %及 30 .7% ,两者相比较 ,差异有显著性意义 (P <0 .0 5 )。有 30例甲状腺癌同时存在ras和 p5 3的过度表达 ,术后 4年中 3例死亡 ,5例复发。 结论 癌基因ras的激活和抑癌基因 p5 3的失活在甲状腺癌发生中有协同作用 ,ras和 p5 3在甲状腺癌的共同表达可能提示预后不良
Objective To investigate the interaction of ras and p53 gene overexpression in the development of thyroid cancer, and the relationship between the clinical pathological criteria of thyroid cancer and the overexpression of ras and p53. Methods LSAB immunohistochemical method was used to detect the expression of ras and p53 in 80 cases of thyroid lesions, including 54 cases of thyroid cancer and 26 cases of benign thyroid nodules. Results The positive expression rates of ras and p53 in thyroid cancer and benign thyroid nodular lesions were 90.7% and 23.0% and 55.5% and 30.7%, respectively. Significantly significant (P < 0.05). Thirty patients with thyroid carcinoma had both ras and p53 overexpressed. Three patients died within 4 years and 5 patients relapsed. Conclusion The activation of oncogene ras and the inactivation of tumor suppressor gene p53 have a synergistic effect in the development of thyroid cancer. The co-expression of ras and p53 in thyroid cancer may indicate a poor prognosis.